胰腺癌免疫特征分析用于放疗联合免疫及靶向治疗:一项随机2期试验的生物标志物分析
该研究为开放标签随机2期试验的二次分析,入组术后局部复发胰腺癌患者,按KRAS突变和PD-L1阳性筛选后随机接受SBRT+帕博利珠单抗+曲美替尼(SBRT+K+M)或SBRT+吉西他滨(SBRT+G)。在SBRT+K+M组,PD-L1+/TIL+患者中位OS为17.2个月,PD-L1+/TIL-为12.7个月(HR 0.62,p=0.036);SBRT+G组两亚组OS无显著差异。结论认为PD-L1、TILs和突变KRAS可能作为生物标志物指导放疗联合免疫及靶向治疗。
要点
- SBRT+K+M组PD-L1+/TIL+中位OS 17.2个月 vs PD-L1+/TIL- 12.7个月(HR 0.62,p=0.036)。
- SBRT+G组PD-L1+/TIL-中位OS 13.1个月 vs PD-L1+/TIL+ 12.7个月(HR 0.97,p=0.896)。
- PD-L1+/TIL-亚组3-4级不良事件:SBRT+K+M组16例(30.8%)vs SBRT+G组9例(16.7%)。
核心结论
- PD-L1、TILs和突变KRAS可能作为生物标志物指导胰腺癌放疗联合免疫及靶向治疗方案的临床实践,前提是进一步联合MEK抑制剂作为靶向治疗。
研究设计与样本
- 开放标签随机2期试验的二次分析,入组术后局部复发胰腺癌患者,要求KRAS突变且PD-L1免疫组化染色阳性。
- 患者随机接受SBRT+帕博利珠单抗+曲美替尼(SBRT+K+M)或SBRT+吉西他滨(SBRT+G),共170例,每组85例。
- 每个治疗臂内按PD-L1+/TIL-和PD-L1+/TIL+分组进行分析。
主要发现
- SBRT+K+M组:PD-L1+/TIL+中位OS 17.2个月(95%CI 14.6-19.8)vs PD-L1+/TIL- 12.7个月(95%CI 10.8-14.6),HR 0.62(95%CI 0.39-0.97),p=0.036。
- SBRT+G组:PD-L1+/TIL-中位OS 13.1个月(95%CI 10.9-15.3)vs PD-L1+/TIL+ 12.7个月(95%CI 9.2-16.2),HR 0.97(95%CI 0.62-1.52),p=0.896。
- SBRT+K+M组3-4级不良事件:PD-L1+/TIL- 16例(30.8%),PD-L1+/TIL+ 10例(30.3%)。
- SBRT+G组3-4级不良事件:PD-L1+/TIL- 9例(16.7%),PD-L1+/TIL+ 8例(25.8%)。
- SBRT+K+M组改善的结局已在先前研究中报告。
关键数值与推荐
- PD-L1+/TIL+且接受SBRT+K+M患者的中位OS为17.2个月(95%CI 14.6-19.8),与PD-L1+/TIL-相比HR 0.62(95%CI 0.39-0.97,p=0.036)。
- PD-L1+/TIL-且接受SBRT+G患者的中位OS为13.1个月(95%CI 10.9-15.3),与PD-L1+/TIL+相比HR 0.97(95%CI 0.62-1.52,p=0.896)。
临床怎么用
- 原文结论认为PD-L1、TILs和突变KRAS可能作为生物标志物指导胰腺癌放疗联合免疫及靶向治疗的临床实践,需进一步联合MEK抑制剂。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Immunotherapy alone offered limited survival benefits in pancreatic cancer, while the role of immunotherapy-centric combined therapy remains controversial. Therefore, it is required to develop biomarkers to precisely deliver immunotherapy-based multimodality for pancreatic cancer. METHODS: This is a secondary analysis of an open label, randomized, phase 2 trial, whereas patients with locally recurrent pancreatic cancer after surgery were enrolled. Eligible patients with mutant KRAS and positive immunohistochemical staining of PD-L1 were randomly assigned to receive stereotactic body radiation therapy (SBRT) plus pembrolizumab and trametinib (SBRT + K + M) or SBRT and gemcitabine (SBRT + G). Meanwhile, patients were classified into PD-L1+/tumor infiltrating lymphocytes [TIL(s)]- and PD-L1+/TIL + group for each arm. RESULTS: A total of 170 patients were enrolled and randomly assigned to receive SBRT + K + M (n = 85) or SBRT + G (n = 85). The improved outcomes have been reported in patients with SBRT + K + M in the previous study. In this secondary analysis, the median overall survival (OS) was 17.2 months (95% CI 14.6-19.8 months) in patients with PD-L1+/TIL + and 12.7 months (95% CI 10.8-14.6 months) in patients with PD-L1+/TIL- (HR 0.62, 95% CI 0.39-0.97, p = 0.036) receiving SBRT + K + M. In SBRT + G group, the median OS was 13.1 months (95% CI 10.9-15.3 months) in patients with PD-L1+/TIL- and 12.7 months (95% CI 9.2-16.2 months) in patients with PD-L1+/TIL+ (HR 0.97, 95% CI 0.62-1.52, p = 0.896). Grade 3 or 4 adverse events were found in 16 patients (30.8%) and 10 patients (30.3%) with PD-L1+/TIL- and PD-L1+/TIL + in SBRT + K + M group respectively; whereas 9 (16.7%) and 8 patients (25.8%) with PD-L1+/TIL- and PD-L1+/TIL + in SBRT + G group. CONCLUSION: PD-L1, TILs and mutant KRAS may be a biomarker to guide clinical practice of radiotherapy and immunotherapy-based regimens in pancreatic cancer if further combined with MEK inhibitors as targeted therapy.
引用
- Zhu X, Liu W, Cao Y, et al. Immune profiling of pancreatic cancer for radiotherapy with immunotherapy and targeted therapy: Biomarker analysis of a randomized phase 2 trial. Radiother Oncol. 2023. PMID: 37820884. doi:10.1016/j.radonc.2023.109941
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。